Support and Resistance Levels
Past performance
About Granules India Ltd Granules India Limited, established in 1991, is a large-scale, vertically integrated pharmaceutical company specializing in the production of Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosages (FD). With significant global reach, servicing over 300 customers in more than 80 countries, Granules holds a strong market position in off-patent drugs and essential products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. The company operates eight manufacturing facilities, including six in India and two in the US, alongside joint ventures in India and China. Granules has made strategic expansions and acquisitions, including the purchase of Auctus Pharma, to enhance its production and diversify its portfolio.
Granules India is known for its robust R&D efforts, with a focus on generic API development and has consistently expanded its manufacturing capacities, notably at its Gagillapur and Bonthapally facilities. The company has successfully navigated regulatory landscapes, evidenced by multiple US FDA approvals and inspections. It continues to innovate, as seen in its expansion into the US market through its subsidiary, Granules Pharmaceuticals Inc., and its recent establishment of a greenfield packaging facility in Virginia. Granules India's commitment to sustainable practices is highlighted by its use of solar energy in its Hyderabad facility.